TY - JOUR
T1 - Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP™), a nutritional supplement
T2 - A case report
AU - Ghafar, Mohamed A.
AU - Golliday, Erica
AU - Bingham, Jonathan
AU - Mansukhani, Mahesh M.
AU - Anastasiadis, Aristotelis Georgios
AU - Katz, Aaron E.
PY - 2002
Y1 - 2002
N2 - Purpose: It has been reported that genistein, an isoflavone used in soybeans, has antiprostate cancer effects. Genistein Combined Polysaccharide (GCP™; AMino Up, Sapporo, Japan), a nutritional supplement manufactured in Japan, is composed of genistein and a polysaccharide obtained from basidiomycetes (mycelia) that grows in a variety of mushrooms. Methods: We report a case of a patient with a biopsy proven prostate cancer showing clinical and pathologic evidence of regression following administration of GCP. The patient was enrolled in an Institutional Review Board (IRB)-approved protocol and received GCP for 6 weeks prior to radical prostatectomy. Results: The patient's prostate-specific antigen (PSA) decreased from an initial value of 19.7 to 4.2 ng/mL after 44 days of low-dose GCP. No cancer was identified in the radical prostatectomy specimen and no side effects were observed in this patient. Conclusion: This case suggests that GCP, which has shown potent inhibitory effects against prostate cancer in vitro, may have some potential activity in the treatment and prevention of prostate cancer.
AB - Purpose: It has been reported that genistein, an isoflavone used in soybeans, has antiprostate cancer effects. Genistein Combined Polysaccharide (GCP™; AMino Up, Sapporo, Japan), a nutritional supplement manufactured in Japan, is composed of genistein and a polysaccharide obtained from basidiomycetes (mycelia) that grows in a variety of mushrooms. Methods: We report a case of a patient with a biopsy proven prostate cancer showing clinical and pathologic evidence of regression following administration of GCP. The patient was enrolled in an Institutional Review Board (IRB)-approved protocol and received GCP for 6 weeks prior to radical prostatectomy. Results: The patient's prostate-specific antigen (PSA) decreased from an initial value of 19.7 to 4.2 ng/mL after 44 days of low-dose GCP. No cancer was identified in the radical prostatectomy specimen and no side effects were observed in this patient. Conclusion: This case suggests that GCP, which has shown potent inhibitory effects against prostate cancer in vitro, may have some potential activity in the treatment and prevention of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=0036671212&partnerID=8YFLogxK
U2 - 10.1089/107555302760253694
DO - 10.1089/107555302760253694
M3 - Article
C2 - 12230910
AN - SCOPUS:0036671212
SN - 1075-5535
VL - 8
SP - 493
EP - 497
JO - Journal of Alternative and Complementary Medicine
JF - Journal of Alternative and Complementary Medicine
IS - 4
ER -